IgY and FeLV: limited feline evidence and open questions

Veterinary and animal science · 2025

In plain language

A 2025 review brings together studies of IgY, a type of antibody, in viral infections in dogs and cats. For FeLV, the reported finding concerns blood-cell counts after exposure to IgY that did not target the virus; it does not show that IgY neutralizes the virus or reduces its amount in the blood. The cat studies came from a single core research group, had not been independently replicated, and had limitations that make the results difficult to interpret. Whether FeLV-specific IgY can neutralize the virus and reduce its presence in the blood remains unknown.

Scientific detail

The review “Therapeutic applications of IgY in common canine and feline viral diseases,” published in Veterinary and animal science in 2025 (doi: 10.1016/j.vas.2025.100534), included 14 studies according to its abstract, four of which addressed feline infections. Section 3.2 identifies one case series investigating both FIV and FeLV. The exact number of FeLV-infected cats is not reported in the visible source material.

The reviewed feline evidence came from a single core research group and had not been independently replicated. The IgY preparations used did not target feline viral particles. The directly reported FeLV finding concerns blood-cell counts following non-specific IgY exposure, not demonstrated FeLV neutralization or reduced viremia. Findings in dogs cannot establish efficacy against FeLV.

The authors identify small samples, limited randomization, inadequate controls, lack of blinding, heterogeneous protocols, incomplete reporting, and possible publication bias. No formal risk-of-bias assessment was conducted. The supplied material also omits part of Table 2 and adjacent content, limiting assessment of the FeLV study’s exact design and results.

The review could not determine whether weak feline findings reflected the non-specific IgY product or limitations of study design and sample size. Section 4.3 proposes investigating specific anti-FIV and anti-FeLV IgY but provides no experimental confirmation of FeLV neutralization or reduced viremia. These conclusions concern the reviewed literature and do not describe research published after its search.

What we know

The review describes blood-cell counts following non-specific IgY exposure in the context of FeLV, without demonstrating viral neutralization or reduced viremia. The reviewed feline evidence came from a single core group, had not been independently replicated, and used preparations that did not target feline viral particles. Methodological limitations and incomplete reporting constrain interpretation.

What we don't know

This review does not establish whether FeLV-specific IgY can neutralize the virus and reduce viremia. It also could not distinguish whether weak feline findings reflected the product’s lack of specificity or limitations of study design and sample size. The visible material does not report the exact number of FeLV-infected cats, and omissions in the supplied source limit assessment of the exact design and results.

Evidence

Provenance

This project does not diagnose or prescribe. Always consult your veterinarian.